文献速递关节外科

全关节置换术中利福平的应用:比较性研究的系统综述与Meta分析

The Use of Rifampin in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Comparative Studies.
PubMed 文献 · J Arthroplasty · 2022-03-26

该系统综述与Meta分析纳入33项比较性研究,评估利福平在全关节置换术(TJA)尤其假体周围关节感染(PJI)中的作用。对22项比较标准治疗加用利福平治疗PJI的研究进行Meta分析,发现失败率显著降低(26.0% vs 35.9%;OR 0.61,95%CI 0.43-0.86)。利福平的保护效应在包含置换性关节成形术的研究中维持,但在仅采用植入物保留策略的研究中未维持;报告不良事件的研究中不良事件率为20.5%。

要点

  • 22项研究Meta分析显示,标准治疗加用利福平治疗PJI的失败率26.0% vs 35.9%(OR 0.61,95%CI 0.43-0.86)。
  • 利福平的保护效应在包含置换性关节成形术的研究中维持,在仅用植入物保留策略的研究中未维持。
  • 报告利福平不良事件的研究中,不良事件率为20.5%。

核心结论

  • 总体而言,利福平似乎对PJI治疗失败具有保护效应。
  • 该治疗效应在置换性关节成形术背景下尤为明显。
  • 需要进一步高级别证据以明确利福平作为PJI治疗辅助用药的最有效确切适应证和剂量。

研究设计与样本

  • 系统综述与Meta分析,证据等级为Level III,纳入Level I-III研究的系统综述与Meta分析。
  • 检索所有相关电子数据库,纳入所有评估TJA背景下利福平使用的比较性研究。
  • 共33项研究符合纳入标准;对22项比较标准治疗加用利福平治疗PJI的研究进行Meta分析。

主要发现

  • 22项研究Meta分析显示,标准治疗加用利福平治疗PJI的失败率26.0% vs 35.9%(OR 0.61,95%CI 0.43-0.86)。
  • 利福平的保护效应在包含置换性关节成形术作为治疗策略的研究中维持,但在仅使用植入物保留策略的研究中未维持。
  • 在报告利福平不良事件的研究中,不良事件率为20.5%。

关键数值与推荐

  • 22项比较标准治疗加用利福平治疗PJI的研究:失败率26.0% vs 35.9%(OR 0.61,95%CI 0.43-0.86)。
  • 报告利福平不良事件的研究:不良事件率20.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步高级别证据以明确利福平作为PJI治疗辅助用药的最有效确切适应证和剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty (TJA). Rifampin is an antibiotic with the ability to penetrate bacterial biofilms, and thus has been considered as a potentially important adjunct in the prevention and treatment of PJI. The aim of this systematic review is to evaluate and summarize the use of rifampin in TJA, particularly in the context of PJI. METHODS: A literature search of all relevant electronic databases was performed. All comparative studies assessing the use of rifampin in the context of TJA were included. Descriptive data are reported, and a meta-analysis was performed using all studies which compared the addition of rifampin to standard care in treating PJI. RESULTS: A total of 33 studies met inclusion criteria. A meta-analysis of 22 studies comparing the addition of rifampin to standard care for treating PJI found a significant reduction in failure rates (26.0% vs 35.9%; odds ratio 0.61, 95% confidence interval 0.43-0.86). The protective effect of rifampin was maintained in studies which included exchange arthroplasty as a treatment strategy, but not in studies only using an implant retention strategy. Among studies reporting adverse events of rifampin, there was a 20.5% adverse event rate. CONCLUSION: Overall, rifampin appears to confer a protective effect against treatment failure following PJI. This treatment effect is particularly pronounced in the context of exchange arthroplasty. Further high-level evidence is needed to clarify the exact indications and doses of rifampin which can most effectively act as an adjunct in the treatment of PJI. LEVEL OF EVIDENCE: Level III, Systematic Review and Meta-Analysis of Level I-III Studies.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Kruse CC, Ekhtiari S, Oral I, et al. The Use of Rifampin in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Comparative Studies. J Arthroplasty. 2022. PMID: 35346810. doi:10.1016/j.arth.2022.03.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。